Par Drugs and Chemicals Limited
NSE: PARMarket Closed • NSE
Day range
52 week range
Par Drugs and Chemicals Limited closed at INR109.53 (-1.52%) on volume 0.7x its 20-day average, trading 39.15% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved -82.2% QoQ
2024-12-23
EGM Announced
Extra Ordinary General Meeting
2024-09-13
AGM Announced
Annual General Meeting
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
High Cash Flow Conversion: CFO/PAT averaged 1.29x over last 3 years
Attractive Valuation: P/E of 10.3x trades below sector historical averages
Risks
Subject to cyclical raw material and macro industry pressures
Bull case
Market Leadership: Established operational scale in Drug Manufacturers - Specialty & Generic.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Ownership distribution
Category trends
Hover over a period for exact holdings
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 23 Dec 2024 | Extra Ordinary General Meeting | Extra Ordinary General Meeting | — | 23 Dec 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 13 Sept 2024 |
| — | Annual General Meeting | Annual General Meeting | — | 08 Sept 2023 |
| — | Annual General Meeting | Annual General Meeting | — | 01 Sept 2022 |
| 23 Nov 2021 | Dividend | ₹1.25 / share | — | 22 Nov 2021 |
Traded volume and delivery percentage across the latest 7 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Incorporated in 1982, Par Drugs & Chemicals Ltd manufactures APIs and Fine Chemicals[1]
IndiaHealthcare
Is Par Drugs and Chemicals Limited Shariah compliant?
Par Drugs and Chemicals Limited is currently screened as Pending Data under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Interest-bearing debt or Market Cap data unavailable for ratio screening. Financial ratio screening incomplete due to missing balance sheet or market cap data.
What is Par Drugs and Chemicals Limited's current valuation relative to peers?
Par Drugs and Chemicals Limited trades at a P/E of 10.3x compared to the sector median of 37x, and a Price-to-Book of 1.2x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of zero debt. Interest coverage is 105.5x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at steady rates while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.